Grifols S.A. (GRFS)
NASDAQ: GRFS
· Real-Time Price · USD
8.29
-0.01 (-0.12%)
At close: Jun 03, 2025, 3:59 PM
8.34
0.54%
After-hours: Jun 03, 2025, 04:04 PM EDT
Grifols S.A. Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Bio supplies Revenue | 159.96M | 146.08M | 225.76M | 4.24B | 3.99B | 3.52B |
| Bio supplies Revenue Growth | +9.50% | -35.30% | -94.68% | +6.24% | +13.56% | n/a |
| Haemoderivatives Revenue | 5.56B | 5.01B | 3.81B | n/a | n/a | n/a |
| Haemoderivatives Revenue Growth | +11.05% | +31.20% | n/a | n/a | n/a | n/a |
| Other Product Revenue | 203.45M | 250.16M | 39.62M | n/a | n/a | n/a |
| Other Product Revenue Growth | -18.67% | +531.41% | n/a | n/a | n/a | n/a |
| Other diagnostic Revenue | 21.79M | 21.74M | 23.63M | n/a | n/a | n/a |
| Other diagnostic Revenue Growth | +0.23% | -7.98% | n/a | n/a | n/a | n/a |
| Transfusional medicine Revenue | 648.48M | 640.6M | 712.24M | n/a | n/a | n/a |
| Transfusional medicine Revenue Growth | +1.23% | -10.06% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| European Union Revenue | 893.05M | 711.58M | 544.04M |
| European Union Revenue Growth | +25.50% | +30.79% | n/a |
| Rest Of The World Revenue | 1.44B | 1.18B | 872.12M |
| Rest Of The World Revenue Growth | +22.19% | +34.86% | n/a |
| Spain Revenue | 362.88M | 320.63M | 362.41M |
| Spain Revenue Growth | +13.18% | -11.53% | n/a |
| Usa And Canada Revenue | 3.9B | 3.86B | 3.15B |
| Usa And Canada Revenue Growth | +1.12% | +22.22% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 269.48M | 319.43M | 299.69M | 353.2M | 300.32M | 292.12M | 298.89M | 329.71M | 292.82M | 308.47M | 249.86M | 257.14M | 261.35M | 239.9M | 233.78M | 250.59M | 246.65M | 245.15M | 216.66M | 234.36M | 226.74M | 200.26M | 197.45M | 190.32M | 210.19M | 206.37M | 213.78M | 230.01M | 207.31M | 176.13M | 196.76M | 195.06M | 203.18M | 181.06M | 188.37M | 163.82M |
| Selling, General, and Administrative Revenue Growth | -15.64% | +6.59% | -15.15% | +17.61% | +2.81% | -2.27% | -9.35% | +12.60% | -5.07% | +23.46% | -2.83% | -1.61% | +8.94% | +2.62% | -6.71% | +1.60% | +0.61% | +13.15% | -7.55% | +3.36% | +13.22% | +1.42% | +3.75% | -9.45% | +1.85% | -3.46% | -7.06% | +10.95% | +17.71% | -10.49% | +0.87% | -4.00% | +12.22% | -3.88% | +14.98% | n/a |
| Research and Development Revenue | 115M | 87.88M | 90.69M | 113.58M | 88.45M | 87.32M | 100.89M | 106.24M | 93.61M | 85.13M | 86.73M | 71.81M | 80.75M | 71.35M | 74.25M | 67.86M | 75.03M | 68.42M | 69.96M | 62.61M | 70.18M | 58.23M | 58.28M | 53.97M | 106.44M | 60.31M | 62.4M | 59.17M | 47.96M | 52.31M | 49.68M | 47.66M | 66.06M | 54.2M | 53.02M | 50.92M |
| Research and Development Revenue Growth | +30.86% | -3.11% | -20.15% | +28.42% | +1.29% | -13.45% | -5.04% | +13.49% | +9.97% | -1.85% | +20.78% | -11.07% | +13.17% | -3.90% | +9.41% | -9.55% | +9.67% | -2.21% | +11.74% | -10.79% | +20.51% | -0.08% | +8.00% | -49.30% | +76.48% | -3.36% | +5.46% | +23.38% | -8.32% | +5.29% | +4.23% | -27.84% | +21.88% | +2.22% | +4.13% | n/a |